How to access Empaveli from India — the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
An Indian patient with paroxysmal nocturnal hemoglobinuria (PNH) — particularly one who remains anaemic or transfusion-dependent despite prior C5-inhibitor therapy — may be evaluated by their treating haematologist for Empaveli (pegcetacoplan). Empaveli is FDA-approved in the United States and developed by Apellis Pharmaceuticals (partnered with Sobi outside the US). It is a PEGylated C3 complement inhibitor, acting upstream of C5, which allows it to address both intravascular and extravascular haemolysis in PNH. Empaveli is rarely locally registered outside the US and EU, and for Indian patients the named-patient import pathway via CDSCO is the legitimate route.
This guide explains the pathway, what documentation your physician needs, typical costs and timing, and where Reserve Meds fits in.
The clinical situation
Empaveli is administered as a twice-weekly subcutaneous infusion using an infusion pump (commercial mini-pump, delivered over approximately 30 minutes). Because Empaveli inhibits C3 rather than C5, it carries the same class-level warning about encapsulated-organism infections; vaccination (meningococcus, pneumococcus, H. influenzae type B) ahead of therapy is a gating step. Your treating haematologist confirms PNH diagnosis (flow cytometry), prior therapy history, vaccination completion, and the monitoring plan per FDA labeling.
Is Empaveli legally importable into India?
Yes — through the CDSCO / Drugs Controller General of India (DCGI) personal-use and hospital-sponsored named-patient import frameworks. The route permits a registered medical practitioner to request import of a medicine not locally registered when the medicine is approved by a recognised reference authority (FDA qualifies), no clinically equivalent registered option fits, and chain of custody is documented.
For ultra-rare PNH therapy, Indian tertiary haematology centres in Mumbai, Delhi, Bangalore, Chennai, Hyderabad, and Kolkata are experienced with named-patient imports, and diaspora-supported care is a common pattern.
How the pathway works, step by step
- Consultation with your treating haematologist. PNH flow cytometry confirmation, prior therapy history, and clinical rationale.
- Pre-treatment vaccination. Meningococcal, pneumococcal, and Hib vaccinations per labeling — typically at least 2 weeks before first dose or with appropriate prophylaxis.
- CDSCO application. The physician or hospital files the personal-use / named-patient application.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner for Empaveli and the infusion pump / administration supplies.
- Cold-chain shipment. Empaveli ships at 2–8°C with continuous temperature monitoring and chain-of-custody documentation end to end.
- Arrival, training, and ongoing twice-weekly infusion. The haematology unit or home-care partner supports training on the infusion pump; ongoing administration is typically at home after training.
What documentation your physician needs
Your physician will typically need to provide:
- Clinical rationale letter confirming PNH, diagnostic evidence (flow cytometry), prior therapies, and Empaveli as the indicated treatment
- Verification of their Indian medical registration (NMC)
- Patient identifier and address for the import record
- Vaccination documentation
- Planned twice-weekly infusion schedule and training plan
Reserve Meds provides a physician documentation kit that bundles the templates Indian customs and CDSCO reviewers expect to see for complement inhibitors, plus the infusion-pump training note.
Costs and timing
Empaveli's US cash-pay reference price is a high-cost ultra-rare-disease therapy; annualised cost is commonly quoted in a broad indicative range of USD 450,000+ and total course depends on duration of therapy. International cold-chain logistics, customs clearance, CDSCO documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a full transparent quote at the start of intake. These ranges are indicative, not guaranteed.
Indicative timing — not guaranteed — for first dose after cohort intake opens is approximately 21–35 days from the moment a complete application is submitted and customs processing begins, plus vaccination lead time. Ongoing supplies ship on a rolling basis.
Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.
A culturally-aware note: PNH is an ultra-rare condition with long treatment horizons and high cost; Indian diaspora families frequently co-fund care across generations and cities. Our concierge case lead is set up to include every designated family member on coordination and document flow.
Reserve Meds's role
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Empaveli specifically, we provide:
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and for CDSCO / customs review.
- Logistics. Cold-chain, temperature-monitored, internationally tracked shipment of drug and infusion-pump supplies.
- Concierge case lead. A named point of contact.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating haematologist.
Frequently asked
Is this legal in India? Yes, when executed through the CDSCO personal-use / named-patient framework with appropriate documentation.
Why Empaveli rather than a C5 inhibitor? Empaveli inhibits C3 upstream, addressing both intravascular and extravascular haemolysis. For patients who remain anaemic on C5 inhibition, this upstream mechanism can be clinically relevant. Your haematologist will decide.
Can the family abroad pay directly? Yes. Diaspora-supported invoicing is common for ultra-rare-disease care.
Will insurance cover this? Cash-pay is the default. Some Indian insurers and diaspora policies consider ultra-rare-disease named-patient imports on escalated review; we supply documentation for your submission but do not process insurance claims directly.
Next step — join the first-cohort waitlist
Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Empaveli coordination in India.
Add me to the Empaveli waitlist> Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.